**Core Concept**
Bisphosphonates are a class of medications that inhibit bone resorption by targeting osteoclasts, leading to increased bone density and reduced fractures in conditions such as osteoporosis. They work by binding to hydroxyapatite in bone and inhibiting the enzyme farnesyl pyrophosphate synthase, which is essential for the mevalonate pathway, crucial for osteoclast function.

**Why the Correct Answer is Right**
Bisphosphonates are not used in the treatment of hypercalcemia of malignancy caused by parathyroid hormone-related protein (PTHrP) because they do not have a direct effect on PTHrP levels. PTHrP is a humoral factor secreted by many types of cancer cells, and its regulation is not directly influenced by bisphosphonates. In such cases, other treatments like corticosteroids or bisphosphonates targeting PTHrP itself (e.g., denosumab) might be used.

**Why Each Wrong Option is Incorrect**
**Option A:** This choice is not provided, so we cannot evaluate it.
**Option B:** Incorrect, bisphosphonates can be used in osteoporosis and Paget's disease of bone, conditions where bone resorption is excessive.
**Option C:** Incorrect, bisphosphonates can be used in conditions where bone turnover is increased, such as osteoporosis, but not in cases of hypercalcemia of malignancy caused by PTHrP.

**Clinical Pearl / High-Yield Fact**
Bisphosphonates can cause osteonecrosis of the jaw (ONJ) as a rare side effect, especially in patients receiving high doses or with poor oral health. This risk is more pronounced in patients undergoing dental procedures and those with a history of cancer.

**Correct Answer: C.**